SSBP3-AS1: A Potential Drug Target and Biomarker (G619518)

Target Name: SSBP3-AS1

NCBI ID: G619518

SSBP3-AS1

Other Name(s): MST128 | MSTP128 | C1orf191 | SSBP3 antisense RNA 1

SSBP3-AS1: A Potential Drug Target and Biomarker

SSBP3-AS1 (MST128) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the serine/threonine protein kinase (SMPK) family and is involved in the regulation of cell signaling pathways, including neurotransmitter signaling, ion channels, and cytoskeletal organization.

SSBP3-AS1 has been identified as a potential drug target (or biomarker) due to its involvement in several neurological and cardiovascular disorders, including Alzheimer's disease, Parkinson's disease, and hypertension. It is also been shown to play a role in the development of certain types of cancer, such as neuroblastoma.

One of the key mechanisms by which SSBP3-AS1 is involved in neurotransmission is its role as a negative regulator of the neurotransmitter synaptophysin (SNPS) protein. SNPS is a protein that helps to maintain the integrity of the synapse, the chemical barrier that separates neurons from each other. It is thought to play a key role in the regulation of neurotransmitter release and has been implicated in a number of neurological and psychiatric disorders.

Research has shown that SSBP3-AS1 can inhibit the activity of SNPS, which would lead to increased neurotransmitter release and increased neuronal activity. This increase in neurotransmitter release can lead to the exacerbation of symptoms in individuals with neurotransmission disorders, such as Alzheimer's disease and Parkinson's disease.

Another mechanism by which SSBP3-AS1 is involved in neurotransmission is its role as a negative regulator of the voltage-gated sodium channel (VGSC). VGSC is a protein that is responsible for the regulation of neuronal excitability and is thought to play a key role in the development of certain types of cancer.

Research has shown that SSBP3-AS1 can inhibit the activity of VGSC, which would lead to decreased neuronal excitability and reduced cancer cell proliferation. This decrease in neuronal excitability can be beneficial in the treatment of certain types of cancer.

In addition to its role in neurotransmission, SSBP3-AS1 has also been shown to play a role in the regulation of cellular signaling pathways. It is a component of several signaling pathways that are involved in the regulation of cell growth, differentiation, and survival.

One of the most promising aspects of SSBP3-AS1 is its potential as a drug target. Research has shown that inhibiting the activity of SSBP3-AS1 has the potential to treat a wide range of neurotransmission disorders, including Alzheimer's disease, Parkinson's disease, and hypertension.

In addition to its potential as a drug target, SSBP3-AS1 is also of interest as a biomarker for certain types of cancer. The regulation of SNPS and VGSC by SSBP3-AS1 has been shown to be involved in the development of certain types of cancer, such as neuroblastoma.

Overall, SSBP3-AS1 is a protein that is of great interest to researchers due to its involvement in the regulation of cell signaling pathways and its potential as a drug target or biomarker. Further research is needed to fully understand its role in the regulation of cellular processes and its potential as a therapeutic agent.

Protein Name: SSBP3 Antisense RNA 1

The "SSBP3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSBP3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets